secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001683168-23-007815
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharma Q3 net loss narrows to $2.8M; first patient dosed in PH-762 Phase 1b trial
--------------------------------------------------------------------------------

- Q3 net loss $2.8M ($1.14/sh) vs $3.6M ($3.14/sh) in Q3 2022; cash at Sep 30 $8.4M down from $11.8M at Dec 31 2022.
- R&D expenses fell 28% YoY to $1.8M; G&A fell 9% to $1.0M.
- First patient dosed in U.S. Phase 1b trial of intratumoral PH-762 (anti-PD-1) for skin carcinomas (NCT06014086).
- Trial expected to enroll up to 30 patients across 4-6 U.S. sites; neoadjuvant monotherapy with dose escalation.
- Company presented preclinical data on PH-894 (BRD4) and CTLA-4-targeting INTASYL at recent conferences.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316823007815/0001683168-23-007815-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316823007815/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-007815

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer